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H I G H L I G H T S
• CD8+ T-cells in atherosclerotic lesions show impaired IFN-γ and TNF-α production, associated with expression of CD39.
• TCR signaling is required for the upregulation of CD39+ on lesional CD8+ T-cells.
• Pharmacological inhibition of CD39 partly restores cytokine production of CD8+ T-cells in the atherosclerotic lesions.
• CD8+ T-cells from human lesions display increased expression of CD39 compared to their circulating counterparts.






A B S T R A C T
Background and aims: CD8+ T-cells have been attributed both atherogenic and atheroprotective properties, but
analysis of CD8+ T-cells has mostly been restricted to the circulation and secondary lymphoid organs. The
atherosclerotic lesion, however, is a complex microenvironment containing a plethora of inflammatory signals,
which may affect CD8+ T-cell activation. Here, we address how this environment affects the functionality of
CD8+ T-cells.
Methods and results: We compared the cytokine production of CD8+ T-cells derived from spleens and en-
zymatically digested aortas of apoE−/− mice with advanced atherosclerosis by flow cytometry. Aortic CD8+ T-
cells produced decreased amounts of IFN-γ and TNF-α compared to their systemic counterparts. The observed
dysfunctional phenotype of the lesion-derived CD8+ T-cells was not associated with classical exhaustion mar-
kers, but with increased expression of the ectonucleotidase CD39. Indeed, pharmacological inhibition of CD39 in
apoE−/− mice partly restored cytokine production by CD8+ T-cells. Using a bone-marrow transplantation ap-
proach, we show that TCR signaling is required to induce CD39 expression on CD8+ T-cells in atherosclerotic
lesions. Importantly, analysis of human endarterectomy samples showed a strong microenvironment specific
upregulation of CD39 on CD8+ T-cells in the plaques of human patients compared to matched blood samples.
Conclusions: Our results suggest that the continuous TCR signaling in the atherosclerotic environment in the
vessel wall induces an immune regulatory CD8+ T-cell phenotype that is associated with decreased cytokine
production through increased CD39 expression in both a murine atherosclerotic model and in atherosclerosis
patients. This provides a new understanding of immune regulation by CD8+ T-cells in atherosclerosis.
1. Introduction
Atherosclerosis is a chronic inflammatory disease, characterized by
the buildup of arterial plaques that contain both lipids and in-
flammatory cells. Among these cells are the CD8+ T-cells, whose
numbers have been shown to increase as the lesions progress towards
more advanced stages [1]. However, the exact function of CD8+ T-cells
in atherosclerosis remains debated [2]. On the one hand, CD8+ T-cells
can contribute to monocyte recruitment [3] and increased plaque vul-
nerability [4], suggesting a pro-atherogenic role for these cells. On the
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other hand, CD8+ T-cells can mount a cytolytic response against pro-
atherogenic dendritic cells [5] and follicular helper T-cells [6], thereby
limiting atherosclerosis development. Recently, we have shown a pro-
tective role for CD8+ T-cells in the clinically relevant advanced stages
of atherosclerosis [7]. Interestingly, we observed a microenvironment-
specific skewing of CD4+ T-cells upon CD8 depletion, suggesting that
there is an interaction between CD8+ T-cells and the local environment
in the plaque.
The atherosclerotic lesion comprises a complex immunological en-
vironment. Cholesterol accumulates in the arterial intima in the form of
low-density lipoproteins (LDLs). The excess of cholesterol cannot be
cleared and becomes oxidized by various enzymes, forming oxidized
LDL (oxLDL). This, in turn, is able to activate endothelial cells and drive
the recruitment of inflammatory cells into the lesion. Many chemokines
have been associated with atherosclerosis, among which are CCL2,
CX3CL1, and CCL5 [8,9]. The immune cells thus recruited to the plaque
by these chemokines release an array of cytokines such as IFN-γ, TNF-α,
and interleukin (IL)-12, which drives atherogenesis, as well as ather-
oprotective cytokines such as IL-10, IL-13 and transforming growth
factor β [10]. Furthermore, antigen presenting cells (APCs) are able to
process the intraplaque oxLDL and present oxLDL-derived antigens to
induce adaptive immunity. Under the hyperlipidemic conditions in the
lesion, APC migration to peripheral tissue is reduced, resulting in sys-
temic as well as local T-cell activation [11]. Furthermore, cell death
within the lesion due to the ongoing inflammation results in the release
of damage-associated molecular patterns, which further drive the in-
flammatory response [12].
In this study, we aimed to determine how the aforementioned
complex microenvironment in the atherosclerotic lesion affects local
CD8+ T-cells. We used the apolipoprotein E (apoE) knockout mouse
model, which spontaneously develops atherosclerosis on a chow diet in
response to increased plasma cholesterol levels. In these mice, we de-
monstrate that CD8+ T-cells derived from aortic lesions show a dys-
functional phenotype, characterized by impaired cytokine production
when compared to their counterparts in the spleen. This CD8+ T-cell
dysfunction was associated with an increased expression of the ecto-
nucleotidase CD39. We further show that CD39 expression was induced
by TCR signaling, and that pharmacological inhibition of CD39 could
partially reverse the observed phenotypical changes of CD8+ T-cells in
the atherosclerotic microenvironment. Finally, we observed micro-
environment-specific CD39 expression on CD8+ T-cells derived from
human atherosclerosis patients, indicating that the murine results may
be translated to a clinical setting.
2. Materials and methods
2.1. Human studies
Plaques from the carotid artery were obtained after endarterectomy
from 22 anonymous individuals. Matched blood samples were obtained
before surgery from 12 of these patients. The patients underwent en-
darterectomy surgery between December 2017 and April 2018 at the
Haaglanden Medical Center, Westeinde, The Hague, NL. The handling
of all human samples complied with the “Code for Proper Secondary
Use of Human Tissue” and are in accordance with the declaration of
Helsinki regarding ethical principles for medical research involving
human subjects (METC registration number 17–046). Single-cell sus-
pensions were obtained from human plaques as described previously
[13] (see Supplementary Data for a full description).
2.2. Animals
C57Bl/6, LDL receptor (LDLr)−/− and apoE−/− mice were pur-
chased from Jackson Laboratory (Sacramento, CA, USA) and bred in-
house. Animals were kept under standard laboratory conditions; food
and water were provided ad libitum. In order to develop advanced
atherosclerotic lesions in apoE−/− mice, animals were kept on a chow
diet for 30–49 weeks before analysis of T-cell content in the lesion.
Upon sacrifice, mice were subcutaneously anesthetized with an injec-
tion mix of ketamine (100mg/mL), sedazine (25mg/mL) and atropine
(0.5 mg/mL). All animal work was performed in compliance with the
Dutch government guidelines and the Directive 2010/63/EU of the
European Parliament. Experiments were approved by the Ethics
Committee for Animal Experiments of Leiden University.
2.3. Bone marrow transplantation experiment
Bone marrow transplantation was performed as detailed in the
Supplementary Data.
2.4. In vitro CD39 blockade
Splenocytes were derived from a 31 week-old male apoE−/− mouse.
To obtain WBCs, splenocytes were lysed for 1min at room temperature
in lysis buffer (0.15M NH4Cl, 1 mM KHCO3, 0.1mM Na2EDTA; pH 7.3).
CD8+ T-cells were isolated using the CD8+ T-cell isolation kit (Miltenyi
Biotec) according to the manufacturer's protocol. Cells were cultured
for 24 h in the presence of 0, 25, 50 or 100 μM of the CD39 inhibitor
sodium metatungstate (POM-1, Tocris) in RPMI supplemented with
fetal calf serum (10%, PAA), L-glutamine (2%, Lonza), penicillin/
streptomycin (1%, PAA), sodium pyruvate (1%, Sigma-Aldrich) and β-
mercaptoethanol (60 μM, Sigma-Aldrich) at 37 °C and 5% CO2.
2.5. In vivo CD39 blockade
To study the effect of CD39 blockade in vivo, apoE−/− mice with
advanced atherosclerotic lesions (38–47 weeks old) were injected i.p.
with 10mg/kg of POM-1 (Tocris) or with sterile PBS as a control
(n= 5/group). After 24 h, mice were sacrificed as described above.
2.6. Flow cytometry
Flow cytometry was performed as detailed in the Supplementary
Data.
2.7. Statistical analysis
Data are presented as mean ± SEM, the number of animals in each
group is stated in the text. Data were tested for normal distribution and
analyzed by using a two-tailed Student's T-test, Mann-Whitney test,
one-way ANOVA or two-way ANOVA, as appropriate. Statistical ana-
lysis was performed by using Prism (GraphPad). Probability values of
p < 0.05 were considered significant.
3. Results
3.1. Decreased cytokine production by CD8+ T-cells in atherosclerotic
lesions is associated with an upregulation of CD39 expression
Although the presence of CD8+ T-cells in atherosclerosis has been
established, the exact phenotype of these cells within the lesional mi-
croenvironment is as of yet unknown. Here, we examined the difference
in phenotype between CD8+ T-cells derived from aortic lesions and
their counterparts in the spleen in advanced atherosclerosis using the
murine apoE−/− model. Upon 2 h stimulation of these cells with PMA
and ionomycin, we observed a striking 46% decrease in the percentage
of IFN-γ producing CD8+ T-cells (Fig. 1A,C) and a 37% decrease in the
percentage of TNF-α producing CD8+ T-cells (Fig. 1B and D) in the
lesion compared to the spleen. This decreased ability to produce cyto-
kines could indicate that the CD8+ T-cells derived from the lesion are
exhausted. Nonetheless, we found no difference in the expression of the
classical exhaustion markers PD-1 (Fig. 1E) and CTLA4 (Fig. 1F).
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However, using flow cytometry, we did observe a 9-fold increased ex-
pression of the ectonucleotidase CD39 on lesion-derived compared to
splenic CD8+ T-cells (Fig. 1G and H), which could not be explained by a
different ratio of effector and central memory populations in aorta and
spleen (Supplementary Figs. 1A and B). This enzyme hydrolyzes ex-
tracellular ATP into ADP, which can further be converted into adeno-
sine by the ectonucleotidase CD73. Interestingly, aortic CD8+ T-cells
show a slightly lower expression of CD73 compared to splenic CD8+ T-
cells (Supplementary Fig. 1C), which may reflect their activation status
[14]. Interestingly, CD39 has previously been reported to characterize
exhausted CD8+ T-cells during chronic infection [15]. We next set out
to investigate whether CD39-expressing CD8+ T-cells produce fewer
cytokines. Unexpectedly, we observed that CD8+CD39+ T-cells are
able to produce more IFN-γ compared to CD8+CD39− T-cells in both
aorta (13.3% vs. 1.7%, respectively) and spleen (35.6% vs. 9.5%, re-
spectively, Fig. 1I), suggesting CD39 expression does not indicate
Fig. 1. Murine atherosclerotic lesion-derived CD8+ T-cells show a decreased inflammatory phenotype and increased CD39 expression compared to their counterparts
in the spleen.
(A–D) Flow cytometric analysis of the percentages of IFN-γ+ (A,C) and TNF-α+ (B,D) CD8+ T-cells derived from aortas and spleens of apoE−/− mice stimulated for
2 h with PMA and ionomycin. Cells were pregated on live, Thy1.2+CD8+ T-cells. n= 6 (A,C) or n=5 (B,D) apoE−/− mice of 35–49 weeks old, data are re-
presentative of 2 independent experiments. (E–H) Percentages of PD-1+ (E), CTLA-4+ (F) and CD39+ (G,H) CD8+ T-cells derived from aortas and spleens of apoE−/
− mice. Cells were pregated on live, Thy1.2+CD8+ T-cells. n= 3–6 apoE−/− mice of 30–37 weeks old, data are representative of multiple independent experiments.
(I) IFN-γ production by CD39+ and CD39− CD8+ T-cells in the aortas and spleens apoE−/− mice stimulated for 2 h with PMA and ionomycin. Cells were pregated on
live, Thy1.2+CD8+CD39+ or Thy1.2+CD8+CD39− T-cells. n= 6 apoE−/− mice of 41–49 weeks old, data are representative of 2 independent experiments.
Mean ± SEM, *p < 0.05 **p < 0.01 ***p < 0.001.
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exhaustion, but rather reflects the most activated CD8+ T-cells in the
plaque. Notably, although CD39+CD8+ T-cells produce more IFN-γ
than CD39− CD8+ T-cell in the plaque, the production of IFN-γ by both
of these subsets in the aorta is markedly lower compared to their
counterparts in the spleen (Fig. 1I).
3.2. CD39 inhibition can increase cytokine production by CD8+ T-cells in
the lesions
Although CD39 does not appear to mark exhausted CD8+ T-cells in
the atherosclerotic plaque, we did observe decreased cytokine pro-
duction in the aortic compared to the splenic CD8+ T-cells. We,
therefore, hypothesized that the role of CD39 in the stepwise conver-
sion of ATP into adenosine may result in high adenosine levels speci-
fically in the lesion, which has been reported to reduce cytokine pro-
duction [16]. This may allow CD39+CD8+ T-cells to affect cytokine
production of both CD39− T-cells in a paracrine manner as well as
CD39+CD8+ T-cells in an autocrine manner. To test this hypothesis,
CD39 was inhibited by using the small molecule inhibitor sodium me-
tatungstate (POM-1). Ex vivo stimulation of apoE−/− derived splenic
CD8+ T-cells with increasing concentrations of POM-1 resulted in a
dose-dependent increase in IFN-γ production by CD8+ T-cells (Fig. 2A).
The expression levels of CD39 were also slightly increased upon treat-
ment with POM-1 (Fig. 2B). Upon stratification of IFN-γ production by
each subset, it appeared that CD39−CD8+ T-cells (which made up over
80% of all CD8+ T-cells in this experiment) were for the most part
responsible for this marked increase in IFN-γ production, as they
showed a 3.9-fold increase in cytokine production upon treatment with
the highest concentration of POM-1 (Fig. 2C). Within the CD39+CD8+
T-cell subset we only observed a modest 1.7-fold increase in IFN-γ
production. This suggests indeed that CD39 expression may regulate the
cytokine responses of both CD39− and CD39+ cells by affecting para-
crine and autocrine adenosine signaling.
To examine the effects of this inhibitor in vivo, apoE−/− mice were
injected i.p. with 10mg/kg POM-1 or PBS as a control and sacrificed
24 h after treatment. Analysis of the aortic phenotype by flow cyto-
metry revealed a trend towards an increased IFN-γ production by CD8+
T-cells after POM-1 treatment in percentages (3.9% vs. 5.9%, p= 0.079
Fig. 2D,E) and a significant increase in mean fluorescent intensity (470
vs. 617 MFI, Fig. 2F). However, the levels are not returned to those
observed in the spleen. Concomitantly, we observed an increased per-
centage of inflammatory mononuclear cells (CD11b+/Ly6Chigh/Ly6G−)
in the aorta (Supplementary Fig. 2), suggesting the increased IFN-γ
production affected mononuclear cell recruitment and/or activation.
Interestingly, POM-1 treatment increased the production of IFN-γ by
both CD39+ and CD39− CD8+ T-cells. The pro-inflammatory cytokine
production increased by 21% in the CD39−CD8+ subpopulation upon
POM-1 treatment (Fig. 2D and H) and even more prominently by 37%
in CD39+CD8+ T-cells (Fig. 2D and G). This suggests that CD39+CD8+
T-cells in the atherosclerotic lesion, besides inhibiting CD39−CD8+ T-
cells in a paracrine fashion, may maintain a negative feedback loop on
their own inflammatory state through the production of adenosine.
3.3. TCR signaling in the aortic microenvironment induces CD39 expression
Recent work has shown that upon T-cell receptor (TCR) activation,
reactive oxygen species are generated that activate signaling cascades
resulting in increased CD39 expression [16]. Moreover, CD39 has been
reported as a useful marker to discriminate antigen-specific from non-
specific bystander CD8+ T-cells in a tumor environment [17]. As there
is persistent antigen presentation to T-cells in atherosclerotic lesions
[18], we hypothesized that TCR signaling in the aortic microenviron-
ment may cause the observed increase in CD39 expression on the CD8+
T-cells within the lesion, whereas non-specific bystander CD8+ T-cells
do not express CD39. To test this, a bone marrow transplantation ex-
periment was performed in which LDLr−/− mice received 70% CD8−/
− bone marrow combined with either 30% WT or OT.1 bone marrow.
After a 7-week recovery period, mice were fed a Western-type diet for 8
weeks in order to induce atherosclerosis (Fig. 3A). When using this
setup, mice in the OT.1 donor group had only CD8+ T-cells that are
able to recognize ovalbumin through their TCR and were therefore not
able to receive any stimulation from atherosclerosis-specific antigens.
In contrast, mice in the WT donor group had CD8+ T-cells that were
able to receive TCR stimulation. We opted for this “reverse approach” in
which CD8+ T-cells that recognize an irrelevant antigen are compared
to WT cells, as the antigen that activates CD8+ T-cells in atherosclerosis
is as of yet unknown. Strikingly, the number of CD39+CD8+ T-cells in
the lesions of the mice transplanted with the OT.1 bone marrow was
markedly lower when compared to controls (5% vs. 14.6%, Fig. 3B and
C). By extension, the CD8+ T-cells in the OT.1 group also showed a
significantly reduced proliferative capacity, as measured by Ki-67
staining (15.3% vs. 43% Fig. 3D). Thus, TCR signaling is essential for
the increased expression of CD39 on CD8+ T-cells in the atherosclerotic
microenvironment, and CD39 may mark antigen-experienced CD8+ T-
cells in the plaque.
3.4. CD39 expression is increased on CD8+ T-cells derived from human
atherosclerotic lesions compared to their systemic counterparts
We further investigated CD39 expression in human atherosclerotic
lesions to determine whether the results described above are relevant to
human atherosclerosis. CD8+ T-cells derived from carotid en-
darterectomy samples showed a 2.7-fold higher expression of CD39
compared to their counterparts in the blood of these patients (Fig. 4A
and B, for gating strategy, see Supplementary Fig. 3). In agreement with
the murine data, CD8+CD39+ T-cells derived from the lesions pro-
duced more IFN-γ compared to CD8+CD39− cells (30.6% vs. 20.9%,
respectively, Fig. 4C–E). Thus, similar to our findings in apoE−/− mice,
the percentage of CD39+CD8+ T-cells in human atherosclerotic lesions
is strongly increased compared to the blood, and appears to represent
the most activated fraction of CD8+ T-cells in the plaque.
4. Discussion
Atherosclerotic lesions are associated with an influx of CD8+ T-cells
as the lesion progresses towards more advanced stages [1]. As the lesion
microenvironment is very complex, many factors within the lesion may
well affect the phenotype of CD8+ T-cells. It is of particular interest to
understand the function of these cells within the plaque as compared to
their circulating counterparts, as these cells can affect the lesion de-
velopment and composition locally. In this work, we show for the first
time that CD8+ T-cells display an atherosclerotic microenvironment-
specific dysfunction, as aortic-derived CD8+ T-cells produce lower le-
vels of cytokines compared with their counterparts in the spleen.
Chronic antigen stimulation of CD8+ T-cells is known to result in ex-
haustion and an associated reduced cytokine production by these cells
[19]. Antigen-specific stimulation of T-cells also occurs over prolonged
periods of time in atherosclerosis development [20]. We, therefore,
hypothesized that CD8+ T-cells specifically become exhausted in the
lesion microenvironment, as there are high numbers of APCs in the
plaques. Markedly, we found no differences in the expression of the
classical exhaustion-associated inhibitory receptors PD-1 and CTLA-4
[21]. However, high expression of the ectonucleotidase CD39 is linked
to decreased cytokine production and exhaustion of CD8+ T-cells
[15,22], and is also associated with regulatory T-cells [23]. This en-
zyme is involved in hydrolyzing extracellular ATP into ADP which can
be further converted into the immunomodulatory adenosine by ecto-5′-
nucleotidases such as CD73 [24]. ATP is a known danger-associated
molecular pattern which stimulates pro-inflammatory cytokine pro-
duction and has been linked to atherosclerosis [25]. We demonstrated
an increased expression of CD39 on aortic CD8+ T-cells compared to
their splenic counterparts, suggesting a CD39-mediated reduction in
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cytokine production by lesion-derived CD8+ T-cells. We found a slight
decrease in the expression of CD73 on aortic CD8+ T-cells. However,
the rate-limiting step in the aforementioned cascade is CD39 [26], thus
suggesting CD8+ T-cells in advanced atherosclerotic lesions could have
an increased capacity to produce adenosine, although we did not
measure this directly. Bai et al. reported that adenosine produced by
CD8+CD39+ T-cells can drive the exhaustion of CD8+CD39− T-cells
[16]. In agreement with this, we observed higher IFN-γ production by
CD8+CD39+ T-cells compared to their CD39− counterparts within the
aortic microenvironment. As CD39− cells produce fewer cytokines than
their CD39+ counterparts, this may suggest a paracrine regulation of
cytokine production of CD39− cells by CD39+ cells via increased
adenosine-mediated receptor signaling responses (see graphical ab-
stract). Besides decreasing cytokine production of CD8+ T-cells, ade-
nosine-mediated signaling can inhibit Th1 and Th2 CD4+ T-cell de-
velopment, as well as their effector functions [27]. Furthermore,
adenosine can inhibit the function of type 1 cytotoxic CD8+ T-cells
[28], and induce a tolerogenic APC phenotype [29]. This suggests that
the increased CD39 expression on lesion-derived CD8+ T-cells may
have an immune regulatory, and potentially, an atheroprotective
function. Indeed, adenosine signaling via type 1 purigenic receptors
was shown to be protective against atherosclerosis development [30].
However, as we did not measure adenosine levels in situ, we cannot
exclude that there could be an increase in extracellular levels of ADP
Fig. 2. In vivo CD39 blockade in atherosclerotic mice partially restores pro-inflammatory cytokine production in both CD39+CD8+ and CD39−CD8+ T-cells.
(A–C) Purified CD8+ T-cells were derived from the spleen of a 31-week old apoE−/− mouse and cultured for 24 h with the indicated concentrations of POM-1, after
which the cells were stained and analyzed by flow cytometry for CD8+IFN-γ+ (A) and CD8+CD39+ (B) T-cells. (C) IFN-γ production by CD39+ and CD39− CD8+ T-
cells cultured for 24 h under control conditions or with 100 μM of POM-1. Cells were pregated on live, Thy1.2+CD8+ T-cells. (D–G) apoE−/− mice of 42–47 weeks of
age were treated with 10mg/kg POM-1 (n= 5) or sterile PBS (n= 5). After 24 h, aortas were isolated and analyzed by flow cytometry. (D) Representative dot plots
of PBS or POM-1 treated mice showing CD39 and IFN-γ expression on aortic CD8+ T-cells. (E) Percentages and (F) MFI values of IFN-γ expression by CD8+ T-cells.
Cells were pregated on live, CD3+CD8+ T-cells. (G) CD39+CD8+ or (H) CD39−CD8+ T-cells producing IFN-γ. Cells were pre-gated live, CD3+CD8+CD39+ or
CD3+CD8+CD39− T-cells. Mean ± SEM, *p < 0.05 **p < 0.01 ***p < 0.001.
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and AMP as well. These nucleotides can induce both atherogenic sig-
naling [30], but may also induce phosphorylation of the AMP-activated
protein kinase (AMPK) [31]. This phosphorylation results in functional
activation of AMPK, which was shown to reduce atherosclerosis de-
velopment by inducing autophagy and subsequently promoting cho-
lesterol efflux from macrophages, as well as diminishing inflammatory
responses [32].
In this study, we show that CD39 expression directly and indirectly
affects CD8+ T-cell functionality, by inhibiting the enzymatic activity
of CD39 using POM-1. POM-1 has been shown to effectively inhibit ATP
hydrolysis by CD39, and thereby diminish the immunosuppressive
function of tumor-associated macrophages in ovarian cancer [33].
Furthermore, it was shown to inhibit adenosine generation by reg-
ulatory T-cells in a melanoma mouse model [34]. In agreement with
this, we observed an increased IFN-γ production by CD8+ T-cells both
in vitro on splenic-derived CD8+ T-cells and in vivo in the aortas of
apoE−/− mice upon treatment with POM-1. It must be noted that some
off-target effects of the inhibitor may have occurred in vivo, but we
show these effects in vitro on isolated CD8+ T-cells as well, which in-
dicates that the increased cytokine production is most likely due to
reduced adenosine production. Interestingly, we observed an increase
in cytokine production upon POM-1 treatment by both CD39+ and
CD39− CD8+ T-cells, suggesting that the adenosine produced by
CD39+CD8+ T-cells may regulate IFN-γ production in both a paracrine
and autocrine fashion. It must be noted that even though the levels of
IFN-γ production are increased upon POM-1 treatment, they are still not
returned to the levels observed in the spleen. This could be due to their
prolonged exposure to higher concentrations of adenosine in situ. Al-
ternatively, the short duration of treatment may not be able to com-
pletely restore the cytokine production to the levels observed in the
spleen, but we cannot exclude other factors that may contribute to the
decreased cytokine production of CD8+ T-cells in the aortic
Fig. 3. TCR signaling is required to induce CD39 on aortic CD8+ T-cells. (A) Schematic overview of the experimental setup. (B) Representative contour plots
depicting CD39 expression on aortic CD8+ T-cells at sacrifice. (C–D) Percentages of CD39+ (C) and Ki-67+ (D) CD8+ T-cells in the aorta of the mice transplanted
with WT or OT.1 bone marrow at the time of sacrifice as analyzed by flow cytometry. Cells were pregated on live CD8+ T-cells. WT (n = 5) and OT.1 (n = 11),
unequal distribution due to attrition in the experiment. Mean ± SEM, *p < 0.05 **p < 0.01 ***p < 0.001.
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microenvironment. Although we did not investigate this directly, in-
creased CD39 expression on CD8+ T-cells may affect the phenotype and
function of other immune cells present in the lesion. Indeed, it has been
shown that CD39-expressing CD8+ T-cells can suppress CD4+ T-cell
function in a simian immunodeficiency virus infection [35] and sup-
press the proliferative response of Th1 CD4+ T-cells in a myco-
bacterium infection [36]. Full body knockout of CD39 in apoE−/− mice
results in decreased atherosclerosis [37], suggesting an atherogenic role
for this enzyme. However, CD39−/−apoE−/− mice show impaired
platelet activation, enhanced cholesterol efflux and an increase in
plasma HDL, which confirms that a full body knockout of CD39 results
in a number of complex changes in key factors affecting atherosclerosis
development. Similarly, the blocking of CD39 using POM-1 may affect
multiple cell types expressing CD39. Further research that investigates
inhibition or knockout of CD39 specifically on CD8+ T-cells in an
atherosclerotic context is needed to shed more light on the exact role of
CD8+CD39+ T-cells on lesion initiation and progression. We propose
that the increased adenosine produced by these cells functions in an
atheroprotective manner, as blocking of CD39 resulted in increased
IFN-γ production, which is known to drive atherogenesis [38].
Using a bone-marrow transplantation setup in which atherosclerotic
mice are engrafted with bone marrow that gives rise to either wild-type
or ovalbumin-restricted CD8+ T-cells, we were able to demonstrate the
need for TCR signaling for the upregulation of CD39 on lesional CD8+
T-cells. The aortic microenvironment contains many APCs that are able
to locally activate T-cells via their TCR [39]. Upon TCR ligation, re-
active oxygen species (ROS) are generated [40], which in turn are able
to augment the expression of CD39 [16]. As the atherosclerotic lesion
contains many APCs and is characterized by high levels of ROS [41], we
suggest that this local microenvironment boosts CD39 expression on the
CD8+ T-cells. In agreement with our findings, previous reports have
shown that CD39 expression is upregulated on T-cells upon TCR sig-
naling [14,16,22,23]. Moreover, on CD4 regulatory T-cells, the cata-
lytic activity of CD39 was enhanced by TCR ligation [23]. In support of
our findings on CD8+ T-cell skewing by the local microenvironment,
recent work by Simoni et al. has also shown a role for TCR signaling in
inducing CD39 expression on CD8+ T-cells in the tumor micro-
environment [17]. Furthermore, Duhen et al. report a unique tumor-
microenvironment specific population of CD8+ T-cells co-expressing
CD39 and CD103 [42]. Collectively, this suggests that microenviron-
ment specific TCR-signaling is important in inducing CD39 expression
on CD8+ T-cells.
Importantly, we show that in human atherosclerotic lesions CD39 is
upregulated on CD8+ T-cells as well. Moreover, we observed that the
human CD39+ T-cells produce more IFN-γ compared to the CD39− T-
cells, which is in agreement with the phenotype we observed in our
murine model. Thus, it can be presumed that the immunomodulatory
role we observe for CD39+ CD8+ T-cells in apoE−/− mice can be
translated to a clinical setting. This may open up new treatment ave-
nues targeting CD39 expression on CD8+ T-cells in atherosclerosis.
In conclusion, our studies highlight a new role for CD8+ T-cells in
advanced atherosclerosis. We propose that the increased adenosine
produced by CD8+ T-cells inside the lesions acts in an anti-in-
flammatory manner. These results suggest that boosting CD39+CD8+
T-cell function could be an interesting approach for the treatment of
atherosclerosis. As CD39 expression is upregulated in an antigen-spe-
cific manner, vaccination strategies boosting CD8+ T-cell responses,
which have been shown to be effective in a murine model [5], may be a
Fig. 4. CD39 expression on human atherosclerotic lesion-derived CD8+ T-cells is associated with IFN-γ production.
(A–B) Flow cytometry analysis and representative images of CD39 expression on CD8+ T-cells in endarterectomy samples from n=12 arteria carotis or matched
blood. Cells were gated on live CD45+CD3+CD8+ cells. (C–D) Flow cytometry analysis and representative images of IFN-γ production by CD39+ and CD39− CD8+
T-cells in endarterectomy samples from n=12 arteria carotis stimulated for 4 h with PMA and ionomycin. Cells were pregated on live CD45+CD3+CD8+CD39+ or
live CD45+CD3+CD8+CD39− cells. (E) Representative image of IFN-γ production by CD45+CD3+CD8+ T-cells in an unstimulated sample, used to determine the
gating strategy for IFN-γ. Mean ± SEM, *p < 0.05 **p < 0.01 ***p < 0.001.
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